A randomized trial of 91 patients with EGFR-mutant NSCLC evaluated the impact of BRCA1 mRNA expression on PFS when treated with olaparib plus gefitinib or gefitinib alone. This evidence concerns the gene EGFR and non-small cell lung carcinoma.